Anzeige
Mehr »
Login
Dienstag, 30.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Basin Uranium: Es geht los! Der Uran-Superzyklus ist gestartet!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
188 Leser
Artikel bewerten:
(0)

Attention Nu Skin Enterprises, Inc. Investors: Nu Skin Misled Investors According to a Recently Filed Class Action

SAN DIEGO andPROVO, Utah, Feb. 4, 2014 /PRNewswire/ --Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Nu Skin Enterprises, Inc. (NYSE: NUS) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of Utah, Central Division. The complaint alleges that the company and certain of its officers violated the Securities and Exchange Act of 1934 between July 10, 2013 and January 14, 2014 (the "Class Period"). Nu Skin develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex brands.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO)

Nu Skin Is Accused of Failing to Disclose Fraudulent Sales Practices

According to the complaint, shares of Nu Skin common stock lost approximately 18% of its value, falling more than $21 per share to close at $115.23 on January 15, 2014, on news that the company's Chinese operations were in violation of Chinese law and suspected of being a pyramid scheme. Nu Skin shares declined an additional $30.43, or 26% the following day to close at $84.80 in January 16, 2014. Finally, the company's stock dropped an additional $5.23 to close at $79.57on January 17, 2014, on news that China's Ministry of Commerce announced that it would initiate an investigation into the company's practices.

The complaint also alleges that Nu Skin made materially false and misleading statements to investors regarding its business and financial prospects. Specifically, Nu Skin failed to disclose that: (i) the company was in violation of local laws and regulations in China because of its sales and business practices; (ii) the company failed to disclose that these violations would have a negative impact on the company; and (iii) that the company failed to disclose that its much touted growth was unsustainable without its China business.

Nu Skin Shareholders Are Encouraged to Contact Shareholder Rights Law Firm Robbins Arroyo

If you invested in Nu Skin and would like to discuss your shareholder rights, please contact attorney Darnell R. Donahue at (800) 350-6003, DDonahue@robbinsarroyo.com, or via the information form on the firm's shareholder rights blog: http://www.robbinsarroyo.com/shareholders-rights-blog/nu-skin-enterprises-inc

Robbins Arroyo LLP is a nationally recognized leader in securities litigation and shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising.Past results do not guarantee a similar outcome.

Contact:
Darnell R. Donahue
Robbins Arroyo LLP
DDonahue@robbinsarroyo.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com

SOURCE Robbins Arroyo LLP

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2014 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.